Biotech Firm SciSparc Takes Bold Step with 21:1 Share Consolidation
Filing Impact
Filing Sentiment
Form Type
6-K
Rhea-AI Filing Summary
SciSparc Ltd has announced a significant corporate action with a 1-for-21 reverse share split as reported in their Form 6-K filing dated June 28, 2025. This strategic move will consolidate every 21 existing shares into 1 new share.
Key filing details:
- Filing incorporates by reference into multiple registration statements, including Form F-3 (6 filings) and Form S-8 (3 filings)
- Document signed by Oz Adler, who serves as both Chief Executive Officer and Chief Financial Officer
- Company maintains its principal executive offices in Tel Aviv, Israel
- Confirms status as a Form 20-F filer for annual reports
The reverse split announcement suggests a potential strategic effort to meet minimum share price requirements for continued exchange listing or improve the stock's marketability to institutional investors.
Positive
- None.
Negative
- Company implementing a significant 1-for-21 reverse stock split, typically indicating serious share price challenges and potential delisting risk
FAQ
What is SPRC's latest reverse stock split ratio announced in June 2025?
SciSparc Ltd. (SPRC) announced a 1-for-21 reverse share split on June 24, 2025, as disclosed in their Form 6-K filing.
When will SPRC's reverse stock split take effect?
The exact effective date of SPRC's 1-for-21 reverse stock split is not specified in the Form 6-K filing from June 28, 2025. The announcement was made on June 24, 2025.
Who is the current CEO of SPRC as of June 2025?
According to the Form 6-K filing, Oz Adler serves as both Chief Executive Officer and Chief Financial Officer of SciSparc Ltd. (SPRC), as confirmed by his signature dated June 24, 2025.
Which SEC registration statements are affected by SPRC's June 2025 Form 6-K?
This Form 6-K is incorporated into SPRC's Form F-3 registration statements (File Nos. 333-286099, 333-275305, 333-269839, 333-266047, 333-248670, and 333-255408) and Form S-8 registration statements (File Nos. 333-278437, 333-225773, and 333-286791).